🇺🇸 FDA
Pipeline program

MMX Mesalamine/Mesalazine (Low Dose)

SPD476-319

Phase 3 small_molecule completed

Quick answer

MMX Mesalamine/Mesalazine (Low Dose) for Ulcerative Colitis is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Ulcerative Colitis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials